Unicycive Total Current Liabilities vs Short Long Term Debt Total Analysis

UNCY Stock

USD 1.03 0.05 4.63%

Unicycive Therapeutics financial indicator trend analysis is much more than just breaking down Unicycive Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Unicycive Therapeutics is a good investment. Please check the relationship between Unicycive Therapeutics Total Current Liabilities and its Short Long Term Debt Total accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Total Current Liabilities vs Short Long Term Debt Total

Total Current Liabilities vs Short Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Unicycive Therapeutics Total Current Liabilities account and Short Long Term Debt Total. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Unicycive Therapeutics' Total Current Liabilities and Short Long Term Debt Total is 0.15. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Unicycive Therapeutics, assuming nothing else is changed. The correlation between historical values of Unicycive Therapeutics' Total Current Liabilities and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Unicycive Therapeutics are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Total Current Liabilities i.e., Unicycive Therapeutics' Total Current Liabilities and Short Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Unicycive Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Unicycive Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Short Long Term Debt Total

Most indicators from Unicycive Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 12.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.4 M in 2024.

Unicycive Therapeutics fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Non Currrent Assets Other	Other Assets
Total Current Liabilities		0.76	-0.95	0.6	0.69	-0.04	0.58	0.15	1.0	-0.28	-0.55	0.48	0.4	0.83	0.88	-0.14	0.9	0.91	1.0	-0.32	-0.28	0.85	-0.3	-0.02	-0.59	0.94
Net Tangible Assets	0.76		-0.91	0.93	0.88	-0.3	0.83	-0.15	0.78	0.25	-0.81	0.75	0.49	0.85	0.61	-0.51	0.97	0.96	0.77	0.19	-0.51	0.82	0.23	-0.3	-0.96	0.68
Retained Earnings	-0.95	-0.91		-0.81	-0.75	0.18	-0.66	-0.04	-0.95	0.15	0.62	-0.56	-0.41	-0.9	-0.83	0.3	-0.98	-0.98	-0.95	0.2	0.38	-0.9	0.17	0.13	0.77	-0.88
Accounts Payable	0.6	0.93	-0.81		0.77	-0.5	0.78	-0.08	0.61	0.3	-0.71	0.7	0.52	0.84	0.53	-0.45	0.86	0.85	0.61	0.25	-0.38	0.78	0.28	-0.22	-0.93	0.56
Total Current Assets	0.69	0.88	-0.75	0.77		-0.26	0.97	-0.05	0.71	0.5	-0.98	0.95	0.69	0.77	0.57	-0.37	0.84	0.86	0.71	0.45	-0.41	0.74	0.48	-0.22	-0.91	0.63
Common Stock	-0.04	-0.3	0.18	-0.5	-0.26		-0.24	-0.38	-0.02	-0.28	0.21	-0.24	-0.54	-0.31	0.15	-0.23	-0.22	-0.21	-0.07	-0.33	-0.32	-0.04	-0.27	-0.39	0.38	0.11
Total Assets	0.58	0.83	-0.66	0.78	0.97	-0.24		-0.07	0.59	0.59	-0.97	0.99	0.71	0.77	0.56	-0.4	0.76	0.78	0.59	0.55	-0.4	0.76	0.57	-0.24	-0.9	0.59
Short Long Term Debt Total	0.15	-0.15	-0.04	-0.08	-0.05	-0.38	-0.07		0.08	-0.26	0.17	-0.07	0.62	0.31	0.12	0.92	-0.04	-0.03	0.15	-0.15	0.9	0.05	-0.26	0.97	0.15	0.11
Other Current Liab	1.0	0.78	-0.95	0.61	0.71	-0.02	0.59	0.08		-0.26	-0.57	0.5	0.36	0.82	0.88	-0.2	0.91	0.92	1.0	-0.31	-0.35	0.85	-0.28	-0.09	-0.61	0.94
Total Stockholder Equity	-0.28	0.25	0.15	0.3	0.5	-0.28	0.59	-0.26	-0.26		-0.64	0.68	0.43	0.02	-0.3	-0.35	0.03	0.05	-0.26	0.99	-0.23	-0.04	1.0	-0.28	-0.5	-0.29
Net Debt	-0.55	-0.81	0.62	-0.71	-0.98	0.21	-0.97	0.17	-0.57	-0.64		-0.98	-0.64	-0.65	-0.47	0.45	-0.74	-0.75	-0.56	-0.59	0.48	-0.65	-0.62	0.32	0.88	-0.52
Cash	0.48	0.75	-0.56	0.7	0.95	-0.24	0.99	-0.07	0.5	0.68	-0.98		0.72	0.67	0.46	-0.37	0.67	0.69	0.5	0.65	-0.37	0.65	0.67	-0.23	-0.85	0.49
Cash And Short Term Investments	0.4	0.49	-0.41	0.52	0.69	-0.54	0.71	0.62	0.36	0.43	-0.64	0.72		0.7	0.32	0.33	0.47	0.49	0.41	0.49	0.35	0.47	0.42	0.5	-0.59	0.35
Common Stock Total Equity	0.83	0.85	-0.9	0.84	0.77	-0.31	0.77	0.31	0.82	0.02	-0.65	0.67	0.7		0.81	-0.07	0.89	0.89	0.84	0.01	-0.09	0.93	-0.01	0.12	-0.78	0.83
Common Stock Shares Outstanding	0.88	0.61	-0.83	0.53	0.57	0.15	0.56	0.12	0.88	-0.3	-0.47	0.46	0.32	0.81		-0.15	0.75	0.76	0.88	-0.34	-0.27	0.93	-0.32	-0.09	-0.45	0.99
Non Current Liabilities Total	-0.14	-0.51	0.3	-0.45	-0.37	-0.23	-0.4	0.92	-0.2	-0.35	0.45	-0.37	0.33	-0.07	-0.15		-0.39	-0.38	-0.14	-0.23	0.97	-0.3	-0.34	0.97	0.51	-0.17
Other Current Assets	0.9	0.97	-0.98	0.86	0.84	-0.22	0.76	-0.04	0.91	0.03	-0.74	0.67	0.47	0.89	0.75	-0.39		1.0	0.91	-0.02	-0.45	0.88	0.01	-0.21	-0.87	0.82
Other Stockholder Equity	0.91	0.96	-0.98	0.85	0.86	-0.21	0.78	-0.03	0.92	0.05	-0.75	0.69	0.49	0.89	0.76	-0.38	1.0		0.92	-0.01	-0.44	0.88	0.02	-0.2	-0.87	0.83
Total Liab	1.0	0.77	-0.95	0.61	0.71	-0.07	0.59	0.15	1.0	-0.26	-0.56	0.5	0.41	0.84	0.88	-0.14	0.91	0.92		-0.31	-0.28	0.85	-0.29	-0.02	-0.61	0.94
Net Invested Capital	-0.32	0.19	0.2	0.25	0.45	-0.33	0.55	-0.15	-0.31	0.99	-0.59	0.65	0.49	0.01	-0.34	-0.23	-0.02	-0.01	-0.31		-0.11	-0.09	0.99	-0.16	-0.45	-0.34
Short Long Term Debt	-0.28	-0.51	0.38	-0.38	-0.41	-0.32	-0.4	0.9	-0.35	-0.23	0.48	-0.37	0.35	-0.09	-0.27	0.97	-0.45	-0.44	-0.28	-0.11		-0.35	-0.22	0.96	0.47	-0.3
Capital Stock	0.85	0.82	-0.9	0.78	0.74	-0.04	0.76	0.05	0.85	-0.04	-0.65	0.65	0.47	0.93	0.93	-0.3	0.88	0.88	0.85	-0.09	-0.35		-0.06	-0.16	-0.72	0.93
Net Working Capital	-0.3	0.23	0.17	0.28	0.48	-0.27	0.57	-0.26	-0.28	1.0	-0.62	0.67	0.42	-0.01	-0.32	-0.34	0.01	0.02	-0.29	0.99	-0.22	-0.06		-0.27	-0.47	-0.31
Short Term Debt	-0.02	-0.3	0.13	-0.22	-0.22	-0.39	-0.24	0.97	-0.09	-0.28	0.32	-0.23	0.5	0.12	-0.09	0.97	-0.21	-0.2	-0.02	-0.16	0.96	-0.16	-0.27		0.29	-0.09
Non Currrent Assets Other	-0.59	-0.96	0.77	-0.93	-0.91	0.38	-0.9	0.15	-0.61	-0.5	0.88	-0.85	-0.59	-0.78	-0.45	0.51	-0.87	-0.87	-0.61	-0.45	0.47	-0.72	-0.47	0.29		-0.51
Other Assets	0.94	0.68	-0.88	0.56	0.63	0.11	0.59	0.11	0.94	-0.29	-0.52	0.49	0.35	0.83	0.99	-0.17	0.82	0.83	0.94	-0.34	-0.3	0.93	-0.31	-0.09	-0.51

Click cells to compare fundamentals

Unicycive Therapeutics Account Relationship Matchups

Unicycive Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	903K	2.9M	2.1M	3.3M	17.5M	18.4M
Retained Earnings	(3.7M)	(5.9M)	(15.9M)	(34.0M)	(64.5M)	(61.3M)
Accounts Payable	322K	184K	742K	892K	821K	553.9K
Total Current Assets	19K	204K	18.4M	2.6M	13.4M	14.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Unicycive Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Unicycive Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Unicycive Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Unicycive Therapeutics Stock:

How To Invest In Unicycive

Details

Is Unicycive Stock a good investment?

Details

What is Unicycive Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Note that the Unicycive Therapeutics information on this page should be used as a complementary analysis to other Unicycive Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Unicycive Stock analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Transaction History View history of all your transactions and understand their impact on performance
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets

Is Unicycive Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Unicycive Therapeutics. If investors know Unicycive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Unicycive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.28)

Return On Assets

(0.40)

Return On Equity

(2.29)

The market value of Unicycive Therapeutics is measured differently than its book value, which is the value of Unicycive that is recorded on the company's balance sheet. Investors also form their own opinion of Unicycive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Unicycive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Unicycive Therapeutics' market value can be influenced by many factors that don't directly affect Unicycive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Unicycive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Unicycive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Unicycive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Unicycive Total Current Liabilities vs Short Long Term Debt Total Analysis

Total Current Liabilities vs Short Long Term Debt Total

Total Current Liabilities vs Short Long Term Debt Total Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Short Long Term Debt Total

Unicycive Therapeutics fundamental ratios Correlations

Unicycive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unicycive Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Unicycive Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Other Current Liab
Net Working Capital	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Other Current Assets
Cash	+ 0.99	Total Assets

Cash	- 0.98	Net Debt
Net Debt	- 0.98	Total Current Assets
Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Net Debt	- 0.97	Total Assets
Non Currrent Assets Other	- 0.96	Net Tangible Assets